10.1161/01.cir.31.1.5 58 CannonP
In 2014, the Food and Drug Administration (FDA) first approved the use of GLP-1s for weight loss, and the results have been nothing short of transformative for many patients
The binding of GLP-1 (or semaglutide) to GLP-1 receptors activates several biological responses: Increased insulin secretion after food intake, which improves blood glucose levels Reduced glucagon secretion, which limits glucose in the blood and helps reduce spikes in blood sugar Slowed emptying of the stomach, which helps people feel less hungry during the day Suppressed appetite, which again helps with feelings of satiety All of these factors promote sustained food (and therefore calorie) reduction, supporting weight loss with time
A study has suggested that the accumulation of amyloid- (A) deposits triggers a series of pathological processes, such as inflammation, tau angle formation, synaptic dysfunction, and cell death, which lead to neurodegenerative behavior and eventually to the development of dementia (36)
Aunque transitorios en la mayora de los casos, estos sntomas pueden ser molestos, lo que lleva a algunos pacientes a interrumpir el tratamiento prematuramente